Greater Glasgow and Clyde Medicines

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary

MUE 09: Parkinson's Disease in Acute Care

** This bulletin supersedes MUE 01 **

Archived February 2022.

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.

MUE 08: Drug induced QT prolongation

** This bulletin supersedes MUE 02 **

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.

DOAC Prescribing in Patients with Non-Valvular AF and for the Treatment and Prevention of VTE

** This bulletin supersedes MUE 05 **

The FAQ includes:

• Questions relating to indications/appropriateness of DOACs
• Questions relating to choice of DOAC & dose
• Questions relating to DOAC initiation
• Further information and advice
• Decision making algorithms

April 2023 update:

This bulletin is in the process of being replaced with a Medicines Update blog series on DOACs. Blogs in the series published to date include:

• Safe Prescribing of Direct Oral Anticoagulants (DOACs)
• Updated Guidance: Use of DOACs in Patients with Venous Thrombosis and Malignant Disease
• DOAC prescribing and body weight

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.